The kinase inhibitor drugs included in our mathematical model are EGFR, BRaf and MEK inhibitors, which together with their combinations have been clinically used or tested for the treatment of melanoma, colon, gastric, pancreatic, non-small-cell-lung-cancer (NSCLC) and other cancers39, 40, 41, 42, 43, 44. This evidence concerns the gene BRAF and non-small cell lung carcinoma.